Live news related to SANOFI stock (FR0000120578): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The United States Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for treating chronic spontaneous urticaria in children aged two…
Sanofi reports a strong first quarter of 2026 with a 13.6% increase in revenue at constant exchange rates, driven by pharmaceutical launches and recen…
Sanofi made significant gains this Thursday, driven by the release of its first quarter 2026 results and favorable news surrounding its flagship produ…
Sanofi announced that the American Food and Drug Administration has extended the review period for its approval application for Sarclisa in a subcutan…
The European Commission has approved Dupixent (dupilumab) for the treatment of moderate to severe spontaneous chronic urticaria in children aged two t…
Sanofi announces that its drug candidate lunsekimig has met its primary and key secondary endpoints in two Phase 2 studies for moderate to severe asth…
The European Commission has granted conditional marketing authorization for Rezurock (belumosudil) for the treatment of chronic graft-versus-host dise…
On Friday, March 28, Sanofi unveiled positive results from three Phase 3 studies assessing amlitelimab, a monoclonal antibody, for the treatment of mo…
Dupixent (dupilumab), jointly developed by Sanofi and Regeneron, has been approved in Japan for the treatment of moderate to severe bullous pemphigoid…
Sanofi announces the release of its 'Q1 2026 Briefing Document' aimed at assisting investors with financial modeling. This quarterly document addresse…
